Modern concepts on the pathogenesis and treatment of chronic heart failure: focus on the metabolic syndrome and its consequences

Prof. L.V. Zhuravlyova, PHD N.V. Sokolnikova, PHD T.A. Rogachova
Kharkiv national medical university

In recent decades, there has been a steady increase in the prevalence of chronic heart failure worldwide, which is estimated to affect up to 2% of the adult population and up to 10% of the elderly. The pathogenesis of chronic heart failure is closely linked to metabolic syndrome. Metabolic syndrome is observed in 60% of patients with chronic heart failure. The most common and potent risk factors for chronic heart failure are the components of metabolic syndrome such as visceral obesity, hyperinsulinemia, insulin resistance, dyslipidemia, hypertension and type 2 diabetes. Adequate treatment of the main components of metabolic syndrome with lifestyle adjustments and modern drug therapy can inhibit the development and progression of chronic heart failure. This article summarizes the common pathogenetic mechanisms of metabolic syndrome and chronic heart failure, as well as current opportunities for their correction.  

Key words: chronic heart failure, metabolic syndrome, visceral obesity, hyperinsulinemia, insulin resistance, dyslipidemia 

https://doi.org/10.15407/internalmed2022.01.089 

Download.PDF (ukr) 

For cite: 

Журавльова, Л.В. Сучасні уявлення про патогенез і лікування хронічної серцевої недостатності: фокус на метаболічний синдром і його наслідки / Л.В. Журавльова, Н.В. Сокольнікова, Т.А. Рогачова // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2022. – № 1. – С. 89-98. doi:  10.15407/internalmed2022.01.089   

Zhuravlyova, LV, Sokolnikova NV, Rogachova TA. Suchasni uiavlennia pro patohenez i likuvannia khronichnoi sertsevoi nedostatnosti: fokus na metabolichnyi syndrom i yoho naslidky. [Modern concepts on the pathogenesis and treatment of chronic heart failure: focus on the metabolic syndrome and its consequences]. Shidnoevr. z. vnutr. simejnoi med. 2022;1:89-98. Ukrainian. doi: 10.15407/internalmed2022.01.089   

 References: 

  1. Purwowiyoto S, Prawara A. Metabolic syndrome and heart failure: mechanism and management. Medicine and Pharmacy Reports. 2021;94(1):15-21. http://dx.doi.org/10.15386/mpr-1884
  2. Lira V, Soltow Q, Long J, Betters J, Sellman J, Criswell D. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism. 2007;293(4):1062-1068. http://dx.doi.org/10.1152/ajpendo.00045.2007
  3. Tanaka T, Nakatani K, Morioka K, Urakawa H, Maruyama N, Kitagawa N, Katsuki A, Araki-Sasaki R, Hori Y, Gabazza E, Yano Y, Wada H, Nobori T, Sumida Y, Adachi Y. Nitric oxide stimulates glucose transport through insulin-independent GLUT4 translocation in 3T3-L1 adipocytes. European Journal of Endocrinology. 2003;149(1):61-67. http://dx.doi.org/10.1530/eje.0.1490061
  4. Cabandugama P, Gardner M, Sowers J. The Renin Angiotensin Aldosterone System in Obesity and Hypertension. Medical Clinics of North America. 2017;101(1):129-137. http://dx.doi.org/10.1016/j.mcna.2016.08.009
  5. Kosmala W, Sanders P, Marwick T. Subclinical Myocardial Impairment in Metabolic Diseases. JACC: Cardiovascular Imaging. 2017;10(6):692-703. http://dx.doi.org/10.1016/j.jcmg.2017.04.001
  6. Sansbury B, Hill B. Regulation of obesity and insulin resistance by nitric oxide. Free Radical Biology and Medicine. 2014;73:383-399. http://dx.doi.org/10.1016/j.freeradbiomed.2014.05.016
  7. Thorp A, Schlaich M. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Journal of Diabetes Research. 2015;2015:1-11. http://dx.doi.org/10.1155/2015/341583
  8. Karwi Q, Sun Q, Lopaschuk G. The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity. Cells. 2021;10(11):3259. http://dx.doi.org/10.3390/cells10113259
  9. Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol. 2021 Nov 6;20(1):218. doi: 10.1186/s12933-021-01408-1. PMID: 34740359; PMCID: PMC8571004.
  10. Chong C, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy. Cardiovascular Research. 2017;113(4):422-430. http://dx.doi.org/10.1093/cvr/cvx018
  11. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 31;17(1):122. doi: 10.1186/s12933-018-0762-4. PMID: 30170598; PMCID: PMC6119242.
  12. Scherer P, Hill J. Obesity, Diabetes, and Cardiovascular Diseases. Circulation Research. 2016;118(11):1703-1705. http://dx.doi.org/10.1161/circresaha.116.308999
  13. Piché M, Tchernof A, Després J. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circulation Research. 2020;126(11):1477-1500. http://dx.doi.org/10.1161/circresaha.120.316101
  14. Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol. 2021 Nov 6;20(1):218. doi: 10.1186/s12933-021-01408-1. PMID: 34740359; PMCID: PMC8571004.
  15. González A, Ravassa S, López B, Moreno M, Beaumont J, San José G, Querejeta R, Bayés-Genís A, Díez J. Myocardial Remodeling in Hypertension. Hypertension. 2018;72(3):549-558. http://dx.doi.org/10.1161/hypertensionaha.118.11125
  16. Tadic M, Cuspidi C. Left Ventricular Remodeling and Masked Hypertension: Don’t Forget Nighttime Diastolic Blood Pressure. American Journal of Hypertension. 2019;32(6):535-537. http://dx.doi.org/10.1093/ajh/hpz047
  17. Sahiti F, Morbach C, Cejka V, Albert J, Eichner FA, Gelbrich G, Heuschmann PU, Störk S. Left Ventricular Remodeling and Myocardial Work: Results From the Population-Based STAAB Cohort Study. Front Cardiovasc Med. 2021 Jun 11;8:669335. doi: 10.3389/fcvm.2021.669335. PMID: 34179134; PMCID: PMC8232934.
  18. Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). Circ Cardiovasc Qual Outcomes. 2021 Apr;14(4):e000102. doi: 10.1161/HCQ.0000000000000102. Epub 2021 Mar 23. PMID: 33755495; PMCID: PMC8059763.
  19. Siragusa M, Fisslthaler B. Insulin Keeps PYK-ing on eNOS. Circulation Research. 2017;120(5):748-750. http://dx.doi.org/10.1161/circresaha.117.310576
  20. De Nigris V, Pujadas G, La Sala L, Testa R, Genovese S, Ceriello A. Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovasc Diabetol. 2015 Aug 22;14:114. doi: 10.1186/s12933-015-0278-0. PMID: 26297582; PMCID: PMC4546318.
  21. Maddox T, Januzzi J, Allen L, Breathett K, Butler J, Davis L, Fonarow G, Ibrahim N, Lindenfeld J, Masoudi F, Motiwala S, Oliveros E, Patterson J, Walsh M, Wasserman A, Yancy C, Youmans Q. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology. 2021;77(6):772-810. http://dx.doi.org/10.1016/j.jacc.2020.11.022
  22. McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
  23. Bozkurt B, Coats A, Tsutsui H, Abdelhamid C, Adamopoulos S, Albert N, Anker S, Atherton J, Böhm M, Butler J, Drazner M, Michael Felker G, Filippatos G, Fiuzat M, Fonarow G, Gomez‐Mesa J, Heidenreich P, Imamura T, Jankowska E, Januzzi J, Khazanie P, Kinugawa K, Lam C, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano G, Sakata Y, Seferović P, Starling R, Teerlink J, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure. 2021;23(3):352-380. http://dx.doi.org/10.1002/ejhf.2115
  24. Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow R. The role of metabolic syndrome in heart failure. European Heart Journal. 2015;36(39):2630-2634. http://dx.doi.org/10.1093/eurheartj/ehv350
  25. Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. Mediators of Inflammation. 2016;2016:1-10. http://dx.doi.org/10.1155/2016/3634948
  26. Yang D, Yang Y, Li Y, Han R. Physical Exercise as Therapy for Type 2 Diabetes Mellitus: From Mechanism to Orientation. Annals of Nutrition and Metabolism. 2019;74(4):313-321. http://dx.doi.org/10.1159/000500110
  27. Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio D, Davies M. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;43(2):487-493. http://dx.doi.org/10.2337/dci19-0066
  28. Verdecchia P, Reboldi G, Angeli F. The 2020 International Society of Hypertension global hypertension practice guidelines – key messages and clinical considerations. European Journal of Internal Medicine. 2020;82:1-6. http://dx.doi.org/10.1016/j.ejim.2020.09.001
  29. Unger T, Borghi C, Charchar F, Khan N, Poulter N, Prabhakaran D, Ramirez A, Schlaich M, Stergiou G, Tomaszewski M, Wainford R, Williams B, Schutte A. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357. http://dx.doi.org/10.1161/hypertensionaha.120.15026
  30. Mach F, Baigent C, Catapano A, Koskinas K. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-188.
  31. Dunlay S, Givertz M, Aguilar D, Allen L, Chan M, Desai A, Deswal A, Dickson V, Kosiborod M, Lekavich C, McCoy R, Mentz R, Piña I. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):294-324. http://dx.doi.org/10.1161/cir.0000000000000691
  32. Hirano T. Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis. 2018;25(9):771-782. http://dx.doi.org/10.5551/jat.rv17023
  33. Cosmi F, Shen L, Magnoli M, Abraham W, Anand I, Cleland J, Cohn J, Cosmi D, De Berardis G, Dickstein K, Franzosi M, Gullestad L, Jhund P, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni A, Masson S, McMurray J, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure. 2018;20(5):888-895. http://dx.doi.org/10.1002/ejhf.1146
  34. Cuthbert J, Pellicori P, Clark A. <p>Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data</p>. Therapeutics and Clinical Risk Management. 2020;16:715-726. http://dx.doi.org/10.2147/tcrm.s234772
  35. Januzzi J, Prescott M, Butler J, Felker G, Maisel A, McCague K, Camacho A, Piña I, Rocha R, Shah A, Williamson K, Solomon S. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085. http://dx.doi.org/10.1001/jama.2019.12821
  36. Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L77-L81. doi: 10.1093/eurheartj/suaa140. PMID: 33727901; PMCID: PMC7944492.
  37. Jhund P, Ponikowski P, Docherty K, Gasparyan S, Böhm M, Chiang C, Desai A, Howlett J, Kitakaze M, Petrie M, Verma S, Bengtsson O, Langkilde A, Sjöstrand M, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021;143(20):1962-1972. http://dx.doi.org/10.1161/circulationaha.121.053659
  38. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.
  39. Packer M, Anker S, Butler J, Filippatos G, Ferreira J, Pocock S, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology. 2021;77(11):1381-1392. http://dx.doi.org/10.1016/j.jacc.2021.01.033
  40. Maagaard M, Nielsen EE, Gluud C, Jakobsen JC. Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis. Syst Rev. 2019 Feb 1;8(1):39. doi: 10.1186/s13643-019-0957-0. PMID: 30709418; PMCID: PMC6357471.